Telix Pharmaceuticals
Presence
Telix Pharmaceuticals is one of the...
Telix Pharmaceuticals is a company listed under the stock ticker TLX (AU).
Telix Pharmaceuticals has a direct presence in 3 countries.Telix Pharmaceuticals has 3 subsidiaries including Telix Pharmaceuticals Americas, Telix Pharmaceuticals APAC and Telix Pharmaceuticals EMEA.
Executives
View the org chart displaying its 34 main executives
Most searched biographies at Telix Pharmaceuticals
- Christian Behrenbruch, Director, Group Managing Director and Chief...
- Mark Nelson, Non-Executive Director
- Andreas Kluge, Non-Executive Director
Popular executive movements at Telix Pharmaceuticals
- Darren Patti, who was US Chief Operating Officer and General Manager, Americas, is promoted to Group Chief Operating Officer (posted on March 13 2024).
- Colin Hayward, Chief Medical Officer, will leave the company on Dec. 31, 2023 (posted on December 21 2023).
- David Cade who is Chief Executive Officer, Asia-Pacific, will be promoted to Group Chief Medical Officer on Jan. 1, 2024 (posted on December 20 2023).
Create your alert
to follow the executive moves at Telix Pharmaceuticals.
Pharmaceuticals
Telix Pharmaceuticals has 1,860 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- MedMen has filed for bankruptcy protection (posted on April 28 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Telix Pharmaceuticals
- Telix Completes Acquisition of ARTMS, and its Advanced Isotope Production Platform | Telix Pharmaceuticals
- TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation | Telix Pharmaceuticals
- TLX250-CDx (Zircaix®) Recognised in EAU Guidelines as an Emerging Technology for the Management of RCC (Kidney Cancer) | Telix Pharmaceuticals
- Q1 2024 Revenue and Business Update | Telix Pharmaceuticals
- Telix Pharmaceuticals Acquires Glioblastoma Program from Therapeia | Telix Pharmaceuticals
- Telix Completes Acquisition of IsoTherapeutics | Telix Pharmaceuticals
- Telix GM 2024 | Telix Pharmaceuticals
- Telix to Present Phase III ProstACT GLOBAL Study (TLX591 Therapy) and Phase II STARBURST Study (TLX250-CDx Indication Expansion) at EAU | Telix Pharmaceuticals
- World First Use of Lightpoint’s SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain | Telix Pharmaceuticals
- First Patient Dosed in Italian Named Patient (Early Access) Program for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent | Telix Pharmaceuticals
- View more press releases Close
Social media about Telix Pharmaceuticals
- Telix Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Telix Pharmaceuticals on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Christian Behrenbruch 
Call Telix Pharmaceuticals at +61 44...
